Related Experiment Video
Updated: Aug 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
-Anticoagulation after intracoronary stent implantation-
Insights
Intracoronary stents improve percutaneous transluminal coronary angioplasty outcomes but carry thrombosis risks. New antithrombotic strategies and stent designs are crucial for managing these risks and improving patient safety.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) success is limited by acute dissection/occlusion and chronic restenosis.
- Intracoronary stents effectively manage acute complications and reduce restenosis but pose a risk of stent thrombosis due to thrombogenic surfaces.
- Stent thrombosis is influenced by emergency implantation, low coronary blood flow, small vessel diameter, and multiple stent placements.
Purpose of the Study:
- To review the role of anticoagulation and platelet inhibition in mitigating stent thrombosis.
- To evaluate the efficacy and safety of various antithrombotic therapies post-stent implantation.
- To explore emerging strategies for reducing stent thrombosis, including novel antithrombotics and stent designs.
Main Methods:
- Review of major randomized studies (BENESTENT, STRESS) evaluating antithrombotic regimens.
- Analysis of outcomes associated with combination therapies including aspirin, dipyridamole, dextran, heparin, and warfarin.
- Examination of recent findings on aspirin and ticlopidine combination therapy and novel antithrombotic agents.
Main Results:
- Early combination therapies (aspirin, dipyridamole, dextran, heparin, warfarin) led to high rates of bleeding and vascular complications.
- Dipyridamole and dextran were found to not improve outcomes after stent implantation.
- Aspirin and ticlopidine combination therapy has shown promise in reducing stent thrombosis rates.
- Predictive markers for stent thrombosis have not yet been successfully identified.
Conclusions:
- Optimal stent implantation may allow anticoagulation management without warfarin, reducing bleeding risks.
- Despite accurate anticoagulation monitoring, stent thrombosis remains a concern.
- Emerging antithrombotic agents (hirudin, antibody 7E3) and reduced thrombogenicity of new stents offer promising future directions for preventing stent thrombosis.
Abstract:
The success of percutaneous transluminal coronary angioplasty (PTCA) is limited by vessel dissection with subsequent vessel occlusion in the acute phase and by restenosis chronically. The implantation of intracoronary stents allows to manage acute complications more efficiently and reduce restenosis rate. Anticoagulation and inhibition of platelet function play an important role in reducing the risk of stent thrombosis triggered by the thrombogenic surface of the stents available today. Among the risk factors for stent thrombosis are stent implantations in emergency situations, a low coronary blood flow secondary to more distal stenoses or to small vessel diameter, and several stents implanted in a single vessel region. In 2 large randomized studies (BENESTENT, STRESS), combination therapy using aspirin, dipyridamole, dextrane, and heparin continued by warfarin lead to a high incidence of bleedings and vascular complications at the site of arterial punction. Subsequent studies documented that dipyridamole and dextrane do not improve the outcome after stent implantation. Recently, the combination of aspirin and ticlopidine has been show to reduce the rate of stent thrombosis; with coronary stents implanted optimally anticoagulation may be handled without warfarin. Most stent thromboses occur even if anticoagulation is monitored and controlled accurately. The search for markers to predict stent thrombosis such as the prothrombin fragment F1+2 or the thrombin-antithrombin complex has not been successful so far. The direct antithrombin hirudin, platelet receptor blockers such as the antibody 7E3, and new stents with reduced thrombogenic surface offer new perspectives in anticoagulation with stent implantation.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Venous Thrombosis III: Interprofessional Care

